Patents Examined by Sudhakar Katakam
  • Patent number: 11072637
    Abstract: The present invention provides a walnut oligopeptide powder, a preparation method and application thereof. The oligopeptide powder has a peptide content of 80 wt % or higher, in which 95% or more of the peptides have a molecular weight of less than 1,500 Da. The method includes extracting walnut proteins using a highly efficient countercurrent extraction process, and subjecting the extract to filtration, enzymolysis, purification with a microfiltration membrane and an ultrafiltration membrane, concentrating, and spray drying to obtain the oligopeptide powder. The oligopeptide powder has an anti-oxidant activity and provides a protective effect for a neuron, and thus can ameliorate or treat memory deterioration and relieve fatigue.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: July 27, 2021
    Assignee: SINPHAR TIAN-LI (HANGZHOU) PHARMACY COMPANY LIMITED
    Inventors: Zhaori Wang, Mingchuan Liu, Shengjie Yang, Da Hong, Jinping Yang
  • Patent number: 11072635
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: July 27, 2021
    Assignees: RQX Pharmaceuticals, Inc., Genentech, Inc.
    Inventors: Yongsheng Chen, Peter Andrew Smith, Tucker Curran Roberts, Robert I. Higuchi, Prasuna Paraselli, Michael F. T. Koehler, Jacob Bradley Schwarz, James John Crawford, Cuong Q. Ly, Huiyong Hu, Zhiyong Yu
  • Patent number: 11071728
    Abstract: Aspects of the invention relate generally to the treatment of schizophrenia and to monitoring for specific adverse reactions.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: July 27, 2021
    Assignee: Vanda Pharmaceuticals Inc.
    Inventor: Mihael H. Polymeropoulos
  • Patent number: 11072686
    Abstract: An integrated process for manufacturing polyethyleneamine compounds selected from the group of polyethyleneamines and hydroxyethylethyleneamines is provided.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: July 27, 2021
    Assignee: NOURYON CHEMICALS INTERNATIONAL B.V.
    Inventors: Rens Veneman, Antoon Jacob Berend Ten Kate, Michiel Jozef Thomas Raaijmakers, Slavisa Jovic, Rolf Krister Edvinsson, Eike Nicolas Kantzer, Karl Fredrik Lake, Ina Ehlers, Hendrik Van Dam
  • Patent number: 11066439
    Abstract: The present invention relates to the efficient solid-phase synthesis of liraglutide represented by Formula-I. The present invention relates to an efficient process for the preparation of liraglutide by sequential coupling employing solid phase approach. It involves sequential coupling of protected amino acids to prepare backbone of liraglutide and upon completion of linear sequence, synthesis was extended from lysine side chain by adding ?-glutamic acid and palmitic acid, followed by removal of protective groups, cleavage of the peptide from solid support and purification of crude liraglutide obtained. The present invention also involves the usage of inorganic salts during the coupling, wash with HOBt in DMF solution after Fmoc-deprotection step to suppress the aggregation of peptides and ensure reactions are going for completion, and thus avoid deletion sequences and improve the process yield.
    Type: Grant
    Filed: December 9, 2017
    Date of Patent: July 20, 2021
    Assignee: Biocon Limited
    Inventors: Ramu Vasanthakumar Ganga, Nitin Patil, Palle Venkata Raghavendra Charyulu, Castelino Roopa Jasmine, Rambabu Machani, Deepa Shankar Suvarna
  • Patent number: 11066445
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: July 20, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Li-Qiang Sun, Eric Mull, David R. Langley, Paul Michael Scola
  • Patent number: 11066354
    Abstract: The invention relates to a process for the preparation of a compound represented by formula (I) wherein X is selected from the group consisting of —H, -halogen, linear or branched C1-C7 alkyl group, linear or branched C1-C5 alkoxy group, —NO2 and —CN and Y is a linear or branched C1-C7 alkyl group, comprising the steps of: 10 a) reacting a compound represented by formula (II) with a compound represented by (III) to obtain an intermediate product, wherein X is as defined with respect to formula (I), wherein Z is H, CH3 or C2H5, b) reacting the intermediate product of step a) with a compound represented by Y2SO4 (IV) wherein Y is as defined with respect to formula (I) to obtain a salt and c) hydrolyzing the salt of step b) to obtain the compound of formula (I).
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: July 20, 2021
    Assignee: SABIC GLOBAL TECHNOLOGIES B.V.
    Inventors: Prashant Sukumar Shinge, Jaiprakash Brijlal Sainani
  • Patent number: 11066443
    Abstract: The present invention relates to compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof for the use in the treatment or prevention of infections and resulting diseases caused by Pseudomonas aeruginosa.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: July 20, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Alanine, Kurt Amrein, Konrad Bleicher, Bernhard Fasching, Hans Hilpert, Sabine Kolczewski, Carsten Kroll, Adrian Schaeublin, Claudia Zampaloni
  • Patent number: 11058746
    Abstract: The present invention provides a method of preventing or treating fibrosis in a subject, comprising administering an effective amount of an immunomodulatory protein derived from Ganoderma lucidum, Ganoderma lucidum, Ganoderma tsugae, Ganoderma microsporum or Ganoderma sinensis to the subject, thereby preventing or treating a fibrosis.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: July 13, 2021
    Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.
    Inventor: Cheng-Chia Yu
  • Patent number: 11059773
    Abstract: The present invention discloses a type-B crystal form of fenolamine, a preparation method thereof, and a composition and use thereof, more particularly a type-B crystal form of the fenolamine compound (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenylethyl)acrylamide, a preparation method thereof, and a composition and use thereof. Specifically, the present invention discloses the presence of a solid of a type-B fenolamine crystal form in solid state; a method for preparing the solid of type-B crystal form; and use of the solid of the type-B fenolamine crystal form as a pharmaceutical active ingredient in the manufacture of a medicament for prevention and treatment of Parkinson's disease (PD), improvement of learning and memory disorder, and treatment of memory loss and Alzheimer's disease (AD).
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 13, 2021
    Assignees: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES, SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
    Inventors: Yang Lv, Shiying Yang, Gengtao Liu, Dan Zhang, Xiuqi Bao, Ping Xie
  • Patent number: 11053277
    Abstract: The present invention relates to a novel process for preparation of peptides having amino acid chain length in the range of 2-40 comprises the steps: i) attaching an end-blocked amino acid with an ionic liquid based solid support in presence of an ionic solvent to obtain an end-terminal blocked amino acid attached ionic liquid; ii) removing end-terminal blocking agent from the end-terminal blocked amino acid attached ionic liquid of step i) followed by work up to obtain an amino acid attached ionic liquid; iii) repeating steps i) through ii) one or more times to obtain a polypeptide attached ionic liquid; and iv) detaching the polypeptide from the polypeptide attached ionic liquid of step iii) to obtain the polypeptide. Said process does not use any auxiliary reagents like dehydrating agent or activating agent. The use of ionic liquids as supports as well as solvents result in the faster kinetics of the process, the separation issues are reduced, and the process has no racemization issues.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: July 6, 2021
    Inventors: Sreedevi Upadhyayula, Tanmoy Patra, Subhasis Paul
  • Patent number: 11046743
    Abstract: The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: June 29, 2021
    Assignee: ANTAROS MEDICAL AB
    Inventors: Torsten Haack, Oliver Plettenburg, Andreas Evers, Michael Wagner, Martin Bossart, Romain Bertrand
  • Patent number: 11044907
    Abstract: The invention provides activated or inactivated compositions combining quaternary ammonium compounds and anionic surfactants or acids. The invention further provides activated or inactivated compositions combining quaternary ammonium compounds and anionic chelants or polymers. Activated antimicrobial compositions comprised of a quaternary ammonium compound having less than a C20 chain length, and an anionic carboxylate surfactant having C6-C10 chain length are disclosed. Activated compositions of the invention have a pH of between about 1 and 7 and are substantially free of silanes, sulfates and oxidants. Inactivated antimicrobial compositions comprised of a quaternary ammonium compound having less than a C-20 chain length, and an anionic sulfate or sulfonate surfactant are disclosed. Compositions of the invention have a 10 mole to 1 moles ratio of quaternary ammonium compound to anionic surfactant or about 1 mole to 10 moles ratio. Methods of making and employing the compositions are disclosed.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: June 29, 2021
    Assignee: Ecolab USA Inc.
    Inventors: Victor Fuk-Pong Man, Derrick Richard Anderson
  • Patent number: 11045439
    Abstract: Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: June 29, 2021
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATION
    Inventors: Umut Ozcan, Joseph Majzoub, Ralph Mazitschek
  • Patent number: 11046637
    Abstract: The invention relates to a new process for the manufacture of fluoroaryl compounds and derivatives thereof, in particular of fluorobenzenes and derivatives thereof, and especially wherein said manufacture relates to an environmentally friendly production of the said compounds. Thus, the present invention overcomes the disadvantages of the prior art processes, and in a surprisingly simple and beneficial manner, and as compared to the prior art processes, in particular, the invention provides a more efficient and energy saving processes, and also provides a more environmentally friendly process, for the manufacture of nuclear fluorinated aromatics, and preferably of nuclear fluorinated fluorobenzenes. Accordingly, in one aspect of the invention, an industrially beneficial process for preparing fluorobenzenes from halobenzene precursors using HF to form hydrogen halide is provided by the present invention.
    Type: Grant
    Filed: July 20, 2019
    Date of Patent: June 29, 2021
    Inventors: Hongjun Du, Wenting Wu
  • Patent number: 11033629
    Abstract: The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist and an absorption enhancer, the absorption enhancer includes a medium chain fatty acid or a salt of a medium chain fatty acid; and a medium chain fatty acid glyceride. The kappa opioid receptor agonist may be embedded in an oligosaccharide, such as trehalose. Also provided are capsules containing the oral formulations of the kappa opioid receptor agonists and the absorption enhancer of the invention and methods use of these formulations for the prophylaxis and treatment of variety of kappa opioid receptor-associated diseases and conditions such as pain, pruritus and inflammation; the method comprising administering to the mammal the formulation comprising the kappa opioid receptor agonist and an absorption enhancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: June 15, 2021
    Assignee: Cara Therapeutics, Inc.
    Inventors: Bryan R. Wilson, Stephen J. O'Connor
  • Patent number: 11033609
    Abstract: The invention relates to cyclic polypeptides derived from the C-terminus of acetylcholinesterase for use in treating or preventing cancer or metastatic disease.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: June 15, 2021
    Assignee: Neuro-Bio Ltd
    Inventors: Susan Adele Greenfield, Christopher Pepper
  • Patent number: 11033557
    Abstract: Provided are methods for treatment and prevention of ischemia-reperfusion injury and chronic intermittent hypoxia related injury through administering a neuroprotective compound. A subject benefiting from the method of the invention may be prescribed or undergoing anti-VEGF treatment, for example an IVAV treatment regimen, or may be diagnosed with a disorder such as sleep apnea.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: June 15, 2021
    Assignee: Tamara Vrabec
    Inventor: Tamara Vrabec
  • Patent number: 11034756
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: June 15, 2021
    Assignee: ELASMOGEN LIMITED
    Inventors: Caroline Barelle, Mischa Roland Muller, Valarie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • Patent number: 11034727
    Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer and increasing cellular internalization of said peptide compounds. The peptide compounds are selected from the following group consisting of; GVRAKAGVRNMFKSESY as set forth in SEQ ID NO: 9; GVRAKAGVRN(Nle)FKSESY as set forth in SEQ ID NO: 10; and YKSLRRKAPRWDAPLRDPALRQLL as set forth in SEQ ID NO: 11; and wherein at least one protecting group and/or at least one labelling agent is connected to said peptide compound.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: June 15, 2021
    Assignee: TRANSFERT PLUS, S.E.C.
    Inventors: Richard Béliveau, Borhane Annabi, Michel Demeule, Alain Larocque, Jean-Christophe Currie, Cyndia Charfi